Spermosens (SPERM) Q2 2026 earnings summary

Executive summary

• Recruitment for the Generation 3 clinical validation study exceeded expectations, with 44 patients enrolled before the summer break and completion targeted by year-end 2026.

• Expanded partnership discussions across multiple markets, including presentations at major industry congresses and new contacts in Japan.

• Secured a SEK 4.85 million capital facility to support ongoing development and commercialization efforts.

• Focused on partner-led commercialization strategy, aiming for license agreements and scalable distribution.

Financial highlights

• Net sales were SEK 0 for Q2 2026, unchanged from the prior year.

• Operating loss for Q2 2026 was SEK -2,784 thousand, compared to SEK -2,662 thousand in Q2 2025.

• Cash and cash equivalents at period end were SEK 1,878 thousand, down from SEK 11,817 thousand a year earlier.

• Equity at period end was SEK 27,450 thousand, compared to SEK 36,879 thousand in Q2 2025.

• Earnings per share for Q2 2026 were SEK -0.001, improved from SEK -0.02 in Q2 2025.

Outlook and guidance

• Clinical validation study for Generation 3 is on track for completion by the end of 2026.

• Ongoing partner discussions are expected to lead to license agreements in H2 2026.

• Additional capital may be raised through TO6 warrants in November 2026.